- Home
- LOGC vs DMAC Comparison
LOGC vs DMAC Comparison
Compare LOGC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGC
- DMAC
- Stock Information
- Founded
- LOGC 2010
- DMAC 2000
- Country
- LOGC United States
- DMAC United States
- Employees
- LOGC N/A
- DMAC N/A
- Industry
- LOGC Catalog/Specialty Distribution
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- LOGC Consumer Discretionary
- DMAC Health Care
- Exchange
- LOGC Nasdaq
- DMAC Nasdaq
- Market Cap
- LOGC 149.0M
- DMAC 190.2M
- IPO Year
- LOGC 2020
- DMAC N/A
- Fundamental
- Price
- LOGC $6.00
- DMAC $4.29
- Analyst Decision
- LOGC
- DMAC Strong Buy
- Analyst Count
- LOGC 0
- DMAC 3
- Target Price
- LOGC N/A
- DMAC $7.00
- AVG Volume (30 Days)
- LOGC 287.6K
- DMAC 59.2K
- Earning Date
- LOGC 11-05-2024
- DMAC 11-11-2024
- Dividend Yield
- LOGC N/A
- DMAC N/A
- EPS Growth
- LOGC N/A
- DMAC N/A
- EPS
- LOGC N/A
- DMAC N/A
- Revenue
- LOGC $156,000,000.00
- DMAC N/A
- Revenue This Year
- LOGC N/A
- DMAC N/A
- Revenue Next Year
- LOGC $422.91
- DMAC N/A
- P/E Ratio
- LOGC N/A
- DMAC N/A
- Revenue Growth
- LOGC N/A
- DMAC N/A
- 52 Week Low
- LOGC $3.55
- DMAC $2.05
- 52 Week High
- LOGC $6.95
- DMAC $4.95
- Technical
- Relative Strength Index (RSI)
- LOGC 66.92
- DMAC 50.76
- Support Level
- LOGC $5.79
- DMAC $4.18
- Resistance Level
- LOGC $6.04
- DMAC $4.77
- Average True Range (ATR)
- LOGC 0.19
- DMAC 0.19
- MACD
- LOGC 0.03
- DMAC -0.02
- Stochastic Oscillator
- LOGC 88.22
- DMAC 27.27
About LOGC ContextLogic Inc.
ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives a majority of its revenue from Europe and also has a presence in North America; South America, and other countries.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.